Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

Status Completed

Clinical Trial Summary

This study is designed to investigate, whether Sugammadex improves muscle function after standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.

Clinical Trial Description

Muscle relaxants are an integral part of today's anesthesia. They improve intubating conditions and reduce doses of other substances needed for general anesthesia. For ensuring patient safety, neuromuscular function is monitored during general anesthesia. The latter one is only terminated, when neuromuscular monitoring shows an objective normal value. Despite this accurate surveillance, a lot of patients complain about subjectively uncomfortable muscle weakness in the recovery room. A possible explanation for this ostensive contradiction can be the variable "margin of safety" of neuromuscluar transmission in different muscle groups. Waud et al describe this phenomenon, as the fact, that neuromuscular transmission is only clinically detectable, when a certain number of post-synaptic receptors is not blocked. The necessary fraction of free receptors differs a lot between the muscle groups (15-50%). As neuromuscular monitoring only measures one muscle group exemplarily, and a clinically non-detectable number of post-synaptic receptors can be blocked shortly after anesthesia, the subjective muscle weakness of patients could need treatment.

Sugammadex can encapsulate steroid-typ muscle relaxants within 2 to 5 minutes. After applying a sufficiently high dose, also those receptors will be free that elude neuromuscular monitoring. This constellation brings up the interesting problem to quantify the possible effect on patients' subjective muscle weakness.

This study is designed to investigate, if the application of sugammadex improves muscle function and consequently well-being of patients, that have been extubated according to clinical standard. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Neuromuscular Blockade

Clinical Trial Details

NCT number	NCT01101139
Study type	Interventional
Source	Technische Universität München
Contact
Status	Completed
Phase	Phase 4
Start date	April 2010
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05558969` - The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex	N/A
Completed	`NCT03168308` - Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients	Phase 4
Not yet recruiting	`NCT03978780` - Erector Spinae Block vs. Placebo Block Study	N/A
Completed	`NCT02912039` - Electromyographic Assessment of the TetraGraph in Normal Volunteers
Completed	`NCT02892045` - Mindray Neuromuscular Transmission Transducer
Completed	`NCT03427385` - Minimum Local Anesthetic Dose for Adductor Canal Block	N/A
Completed	`NCT01450813` - The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy	N/A
Completed	`NCT00535496` - Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)	Phase 3
Recruiting	`NCT05794503` - Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex	Early Phase 1
Not yet recruiting	`NCT05993390` - Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients	N/A
Recruiting	`NCT04609410` - Bleeding in Laparoscopic Liver Surgery	N/A
Terminated	`NCT03649672` - The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor	N/A
Completed	`NCT05474638` - Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery	N/A
Completed	`NCT05687253` - Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery	Phase 2
Completed	`NCT05120999` - Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
Completed	`NCT03608436` - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery	Phase 4
Completed	`NCT03572413` - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.	Phase 4
Recruiting	`NCT02930629` - Residual Block in Postoperative Anaesthetic Care Unit	N/A
Completed	`NCT02932254` - Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex	Phase 4
Completed	`NCT01828385` - Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.